Flumazenil discrimination by humans under a two-response and a novel- response procedure

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 1257-1268

  Smith, Brandi J ^a,b,c   Bickel, Warren K ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Behavioral Biology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUMAZENIL; MIDAZOLAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; FEMALE; HUMAN; MALE; PERFORMANCE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SEDATION;

ADOLESCENT; ADULT; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUMAZENIL; GABA MODULATORS; HUMANS; MALE; MIDAZOLAM; PSYCHOMOTOR PERFORMANCE; TRIAZOLAM;

EID: 0032731867     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ator NA and Griffiths RR (1983) Lorazepam and pentobarbital drug discrimination in baboons: Cross-drug generalization and interaction with Ro 15-1788. J Pharmacol Exp Ther 226:776-782.
2. Ator NA and Griffiths RR (1997) Selectivity in the generalization profile in baboons trained to discriminate lorazepam: Benzodiazepines, barbiturates and other sedative/anxiolytics. J Pharmacol Exp Ther 282:1442-1457.
3. Baldwin HA and File SE (1988) Reversal of increased anxiety during benzodiazepine withdrawal: Evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor. Brain Res Bull 20:603-606.
4. Bickel WK, Oliveto AH, Kamien JB, Higgins ST and Hughes JR (1993) A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans. J Pharmacol Exp Ther 264:360-367.
5. Chait LD, Uhlenhuth EH and Johanson C-E (1989) Individual differences in the discriminative stimulus effects of D-amphetamine in humans. Drug Dev Res 16: 451-460.
6. Dantzer R and Perio A (1982) Behavioural evidence for partial agonist properties of Ro 15-1788, a benzodiazepine receptor antagonist. Eur J Pharmacol 81:655-658.
7. Darragh A, Lambe R, O'Boyle C, Kenny M and Brick I (1983) Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788. Psychopharmacology 80:192-195.
8. De Vry J and Slangen JL (1985a) Stimulus control induced by benzodiazepine antagonist Ro 15-1788 in the rat. Psychopharmacology 85:483-485.
9. De Vry J and Slangen JL (1985b) The Ro 15-1788 cue: Evidence for benzodiazepine agonist and inverse agonist properties. Eur J Pharmacol 119:193-197.
10. File SE and Pellow S (1986) Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788. Psychopharmacology 88:1-11.
11. France CP and Gerak LR (1997) Discriminative stimulus effects of flumazenil in rhesus monkeys treated chronically with chlordiazepoxide. Pharmacol Biochem Behav 56:447-455.
12. Griffiths RR, Evans SM, Guarino JJ, Roache JD, Furman WR, Liebson I and Schwam EM (1993) Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: Antagonism and precipitated withdrawal. J Pharmacol Exp Ther 266:1163-1174.
13. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B and Woodson P (1990) Low-dose caffeine discrimination in humans. J Pharmacol Exp Ther 252:970-978.
14. Herling S and Shannon HE (1982) Ro 15-1788 antagonizes the discriminative stimulus effects of diazepam in rat but not similar effects of pentobarbital. Life Sci 31:2105-2112.
15. Higgitt A, Lader M and Fonagy P (1986) The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects. Psychopharmacology 89:395-403.
16. Hughes JR, Higgins ST, Bickel WK, Hunt WK, Fenwick JW, Gulliver SB and Mireault GC (1991) Caffeine self-administration, withdrawal, and adverse effects among coffee drinkers. Arch Gen Psychiatry 48:611-617.
17. Hunkeler W, Mohler H, Fieri L, Polc P, Bonetti EP, Cumin R, Schaffner R and Haefely W (1981) Selective antagonists of benzodiazepines Nature (Lond) 290: 514-516.
18. Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man), in Drug Addiction I (Martin WR ed) pp 197-258, Springer-Verlag, New York.
19. Kamien JB, Bickel WK, Oliveto AH, Smith BJ, Higgins ST, Hughes JR and Badger GJ (1994) Triazolam discrimination by humans under a novel response procedure: Effects of buspirone and lorazepam. Behav Pharmacol 5:315-325.
20. Kamien JB, Bickel WK, Smith BJ, Higgins ST and Badger GJ (1997) Secobarbital in humans discriminating triazolam under two-responae and novel-response procedures. Pharmacol Biochem Behav 58:983-991.
21. Kapczinski F, Curran HV, Gray J and Lader M (1994) Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology 114:187-189.
22. Lamb RJ and Henningfield HE (1994) Human d-amphetamine drug discrimination: Methamphetamine and hydromorphone. J Exp Anal Behav 61:169-180.
23. Luddens H and Wisden W (1991) Function and pharmacology of multiple GABA-A receptor subunits. Trends Pharmacol Sci 12:49-51.
24. Martin WR, Sloan JW, Shapiro JD and Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12;245-258.
25. McLeod DR, Griffiths RR, Bigelow GE and Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14:436-466.
26. Nutt DJ, Glue P, Lawson C and Wilson S (1990) Flumazenil provocation of panic attacks. Arch Gen Psychiatry 47:917-925.
27. Oliveto AH, Bickel WK, Hughes JR, Higgins ST and Fenwick JW (1992) Triazolam as a discriminative stimulus in humans. Drug Alcohol Depend 30:133-142.
28. Oliveto AH, Bickel WK, Kamien JB, Hughes JR and Higgins ST (1994) Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure. Psychopharmacology 114:417-423.
29. Rowan GA and Lucki I (1992). Discriminative stimulus properties of the benzodiazepine receptor antagonist flumazenil. Psychopharmacology 107:103-112.
30. Saxon L, Hjemdahl P, Hiltunen AJ and Borg S (1997) Effects of flumazenil in the treatment of benzodiazepine withdrawal - a double-blind pilot study. Psychopharmacology 131:153-160.
31. Schechter MD (1984) Specific antagonism of the behavioral effects of chlordiazepoxide and pentobarbital in the rat. Prog Neuropsychopharmacol 8:359-364.
32. Silverman K and Griffiths RR (1992) Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. J Exp Anal Behav 57:91-107.
33. Smith BJ and Bickel WK (1999). The novel-response procedure in humans. Pharmacol Biochem Behav 64:245-250.
34. Trerar AJ and Way WL (1998) Sedative-Hypnotic Drugs, in Basic and Clinical Pharmacology (Katzurg BG ed) 7th ed, pp 354-371, Appleton and Lange, Stamford, CT.
35. Willets J and Balster RL (1989) Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists. J Pharmacol Exp Ther 249:438-443.
36. A receptor. J Pharmacol Exp Ther 268:570-576.
37. Woolverton WL and Nader MA (1995) Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline. Psychopharmacology 122:230-236.
38. Woudenberg F and Slangen JL (1990) Characterisation of the discriminative stimulus properties of flumazenil. Eur J Pharmacol 178:29-36.